Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Savara ( (SVRA) ).
On October 29, 2025, Savara Inc. announced a $75 million royalty funding agreement with RTW Investments, contingent upon FDA approval of MOLBREEVI for autoimmune PAP by March 31, 2027. This agreement is expected to support the U.S. launch of MOLBREEVI, potentially transforming the treatment landscape for this rare disease, and includes provisions for royalty payments based on U.S. net sales, with a buy-back option for Savara under certain conditions.
The most recent analyst rating on (SVRA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.
Spark’s Take on SVRA Stock
According to Spark, TipRanks’ AI Analyst, SVRA is a Neutral.
Savara’s stock score reflects a company in the developmental stage, with significant financial risks due to its lack of revenue and ongoing cash burn. However, a strong balance sheet and recent financing developments provide some stability. Technical indicators suggest short-term positive momentum, but valuation remains challenging with a negative P/E ratio. The recent loan agreement is a positive step, potentially facilitating future growth and commercialization efforts.
To see Spark’s full report on SVRA stock, click here.
More about Savara
Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Their lead program, MOLBREEVI, is a recombinant human granulocyte-macrophage colony stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Average Trading Volume: 1,417,468
Technical Sentiment Signal: Buy
Current Market Cap: $762.2M
Learn more about SVRA stock on TipRanks’ Stock Analysis page.